2 months ago
NRIX
AnalystsTerence FlynnTerence Flynn's Stock Forecasts
AnalystsTerence Flynn
Sectors:
Analyst Ranking
Top 6%
#277 out of 5212 analysts
Average Return
+17.64%
Win Rate
62%78 out of 126
Risk vs Reward
Poor
Good
Terence Flynn's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Alumis IncALMS | +466.32% | $4.75 | $26.90 | 2025-08-15 - 2026-03-06 | Strong Buy |
Arcus Biosciences IncRCUS | +157.85% | $8.28 | $21.35 | 2025-05-09 - 2026-01-08 | Strong Buy |
Translate Bio IncTBIO1 | +147.91% | $15.07 | $37.36 | 2020-10-05 - 2021-09-14 | Strong Buy |
Blueprint Medicines CorpBPMC | +140.20% | $41.34 | $99.30 | 2017-03-13 - 2018-03-13 | Strong Buy |
Eli Lilly & CoLLY | +139.90% | $314.17 | $753.68 | 2023-03-01 - 2024-02-29 | Strong Buy |
Terence Flynn Analyst Color
Get additional color on Terence Flynn's coverage of popular stocks
2 months ago
ALMS
3 months ago
BMY
3 months ago
MRK
3 months ago
GPCR
3 months ago
AMGN
3 months ago
ABBV
3 months ago
LLY
4 months ago
LLY
5 months ago
LLY
8 months ago
JNJ
8 months ago
RPRX
8 months ago
JNJ
8 months ago
LLY
10 months ago
ABBV
a year ago
JNJ
a year ago
LLY
a year ago
JNJ
a year ago
ABBV
a year ago
MRK
a year ago
JNJ
a year ago
ABBV
2 years ago
LLY
2 years ago
RPRX
2 years ago
ABBV
Terence Flynn's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Eli Lilly & CoLLY | 22 | Strong Buy | $1,313.00 | +32.58% | Maintains | a month ago |
Abbvie IncABBV | 20 | Strong Buy | $270.00 | +17.34% | Maintains | a month ago |
Amgen IncAMGN | 12 | Hold | $309.00 | -16.38% | Maintains | a month ago |
Johnson & JohnsonJNJ | 28 | Strong Buy | $262.00 | +8.99% | Upgrades | a month ago |
Arcus Biosciences IncRCUS | 9 | Hold | $20.00 | -9.54% | Downgrades | 2 months ago |
Nurix Therapeutics IncNRIX | 7 | Strong Buy | $36.00 | +138.41% | Upgrades | 2 months ago |
Alumis IncALMS | 3 | Strong Buy | $33.00 | +22.68% | Maintains | 2 months ago |
Biohaven LtdBHVN | 5 | Strong Buy | $21.00 | +111.69% | Maintains | 2 months ago |
Pfizer IncPFE | 21 | Hold | $27.00 | -0.18% | Maintains | 3 months ago |
Bristol Myers Squibb CoBMY | 11 | Strong Sell | $37.00 | -38.63% | Maintains | 3 months ago |
Merck & Co IncMRK | 19 | Hold | $102.00 | -11.91% | Maintains | 3 months ago |
Structure Therapeutics IncGPCR | 2 | Strong Buy | $125.00 | +116.53% | Maintains | 3 months ago |
Vertex Pharmaceuticals IncVRTX | 3 | Strong Buy | $564.00 | +23.50% | Maintains | 3 months ago |
Organon & CoOGN | 11 | Hold | $9.00 | +37.20% | Maintains | 4 months ago |
Royalty Pharma PLCRPRX | 13 | Strong Buy | $54.00 | +18.92% | Maintains | 5 months ago |
Biontech SeBNTX | 5 | Strong Buy | $131.00 | +29.06% | Maintains | 5 months ago |
United Therapeutics CorpUTHR | 11 | Hold | $435.00 | -9.03% | Maintains | 5 months ago |
Arvinas IncARVN | 8 | Hold | $11.00 | -19.12% | Maintains | 10 months ago |
Crispr Therapeutics AgCRSP | 7 | Strong Sell | $32.00 | N/A | Maintains | a year ago |
Intellia Therapeutics IncNTLA | 5 | Hold | $11.00 | N/A | Downgrades | a year ago |
Blueprint Medicines CorpBPMC | 5 | Strong Buy | $168.00 | N/A | Maintains | 2 years ago |
C4 Therapeutics IncCCCC | 5 | Hold | $8.00 | N/A | Maintains | 2 years ago |
Revance Therapeutics IncRVNC | 7 | Hold | $12.00 | N/A | Maintains | 2 years ago |
Neuehealth IncNEUE | 1 | Strong Buy | $2,880.00 | N/A | Initiates Coverage On | 5 years ago |
Biogen IncBIIB | 2 | Hold | $436.00 | N/A | Maintains | 5 years ago |
Translate Bio IncTBIO1 | 1 | Strong Buy | $342.00 | N/A | Initiates Coverage On | 5 years ago |
Acceleron Pharma IncXLRN | 2 | Hold | $40.00 | N/A | Upgrades | 8 years ago |
Alnylam Pharmaceuticals IncALNY | 1 | Strong Buy | N/A | N/A | Upgrades | 8 years ago |
Kyntra Bio IncKYNB | 1 | Hold | N/A | N/A | Downgrades | 9 years ago |
Bioverativ IncBIVV | 1 | Hold | N/A | N/A | Downgrades | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.